For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 2,793 | 1,281* | 1,181 | 1,074 |
| General and administrative | 1,374 | 764* | 1,324 | 1,235 |
| Total operating expenses | 4,167 | 2,044 | 2,505 | 2,309 |
| Operating loss | -4,167 | -2,044* | -2,505 | -2,309 |
| Interest income, net | 161 | 181* | 113 | - |
| Total other income (expense), net | - | - | - | 143 |
| Other income (expense), net | 3 | 2* | 0 | - |
| Net loss | -4,003 | -1,861 | -2,392 | -2,166 |
| Basic EPS | -0.34 | -0.242 | -0.44 | -0.45 |
| Diluted EPS | - | - | - | -0.45 |
| Basic Average Shares | 11,617,250 | 7,688,610 | 5,468,584 | 4,794,857 |
| Diluted Average Shares | - | - | - | 4,794,857 |
Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp. (PHIO)